Arcturus Therapeutics Holdings Stock In The News
| ARCT Stock | USD 17.51 0.58 3.43% |
Our overall analysis of Arcturus Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Arcturus Therapeutics Holdings. The specific impact of Arcturus Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Arcturus Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Arcturus Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Arcturus Therapeutics Backtesting and Arcturus Therapeutics Hype Analysis.
Arcturus |
Arcturus Therapeutics Today Top News and Investor Outlook
Arcturus Therapeutics Holdings Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Arcturus and other traded companies coverage with news coverage. We help investors stay connected with Arcturus headlines for the 28th of November to make an informed investment decision based on correlating the impacts of news items on Arcturus Stock performance. Please note that trading solely based on the Arcturus Therapeutics Holdings hype is not for everyone as timely availability and quick action are needed to avoid losses.
Arcturus Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Arcturus earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Arcturus Therapeutics that are available to investors today. That information is available publicly through Arcturus media outlets and privately through word of mouth or via Arcturus internal channels. However, regardless of the origin, that massive amount of Arcturus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arcturus Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arcturus Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arcturus Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arcturus Therapeutics alpha.
Arcturus Largest EPS Surprises
Earnings surprises can significantly impact Arcturus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-05-13 | 2019-03-31 | -0.58 | -0.65 | -0.07 | 12 | ||
2018-11-07 | 2018-09-30 | -0.56 | -0.42 | 0.14 | 25 | ||
2024-05-08 | 2024-03-31 | -1.19 | -1.0 | 0.19 | 15 | ||
2019-11-07 | 2019-09-30 | -0.36 | -0.56 | -0.2 | 55 | ||
2020-03-11 | 2019-12-31 | -0.53 | -0.76 | -0.23 | 43 | ||
2022-02-28 | 2021-12-31 | -1.72 | -1.47 | 0.25 | 14 |
Arcturus Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Arcturus Therapeutics Stock. Current markets are slightly bearish. About 58% of major world exchanges and indexes are down. See today's market update for more information.
26th of November 2024
Acquisition by Marantz Jing L. of 11869 shares of Arcturus Therapeutics at 34.92 subject t... at MacroaxisInsider
11th of November 2024
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clini... at businesswire.com
8th of November 2024
Arcturus Therapeutics Holdings Inc Q3 2024 Earnings Call Highlights Strategic Advances ... at finance.yahoo.com
7th of November 2024
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress at businesswire.com
6th of November 2024
Arcturus Therapeutics Holdings Inc Q3 2024 Earnings Report Preview What To Look For at gurufocus.com
5th of November 2024
Arcturus Therapeutics Holdings Inc. Given Consensus Recommendation of Buy by Brokerages at thelincolnianonline.com
31st of October 2024
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Upda... at businesswire.com
24th of October 2024
Arcturus Therapeutics Stock Price Down 6.1 percent Heres Why at thelincolnianonline.com
17th of October 2024
Arcturus Therapeutics executive sells 249,121 in stock at investing.com
13th of September 2024
Japans Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Update... at businesswire.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arcturus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arcturus Therapeutics' short interest history, or implied volatility extrapolated from Arcturus Therapeutics options trading.
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.